Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors

Gelderblom, H. et al. (2003) Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. Clinical Cancer Research, 9, pp. 4101-4107.

Full text not currently available from Enlighten.


Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Devlin, Mr Mark
Authors: Gelderblom, H., Salazar, R., Verweij, J., Pentheroudakis, G., de Jonge, M.J.A., Devlin, M., van Hooije, C., Seguy, F., Obach, R., Prunonosa, J., Principe, P., and Twelves, C.
College/School:College of Medical Veterinary and Life Sciences
Journal Name:Clinical Cancer Research

University Staff: Request a correction | Enlighten Editors: Update this record